Clinical trial of lifestyle interventions for weight management in adults living with MS
Obesity can increase the risk of developing MS and may increase levels of disability in those with established MS. Losing weight can help improve more than just body size, but it can be difficult to do and needs the support of a healthcare team to aid behaviour change. This study will use a tested method […]
STRONG-MS: Bone health and muscle health in MS
This study is a randomised controlled trial evaluating ONERO™. This is a High-intensity Resistance and Impact Training (HiRIT) exercise intervention that has potential benefits for bone health and muscle strength in people with (MS). Qualified physiotherapists will supervise balance exercises, impact movements and weightlifting in twice-weekly, 30-minute sessions. Participation involves a total of 24 months. […]
PLATYPUS – the Australian extension of the OCTOPUS trial
PLATYPUS is the Australian extension of a revolutionary trial based in the United Kingdom (UK) called OCTOPUS, which aims to enroll participants in the UK and Australia over the next few years. OCTOPUS (including PLATYPUS) is a trial which will test multiple treatments with the aim to find one that can slow down, and ultimately […]
Fatigue In Relapsing Multiple Sclerosis – Epstein Barr Virus (FIRMS-EBV) Treatment Trial
Fatigue is a common symptom for many people with MS and it does not respond to traditional MS treatments. It has been suggested that fatigue in MS could relate to chronic infection with the Epstein Barr Virus (EBV). In this clinical trial, two drug therapies with antiviral effects against EBV will be tested for their […]
Phase III, multicentre, randomised, double-blinded, placebo-controlled, MAMS trial of SpironolacTone and famciclOvir in the treatment of Progressive MS to prevent disability progression (STOP-MS)
Multiple sclerosis (MS) is a potentially devastating disease of the central nervous system and progressive MS, which occurs in up to two-thirds is the most severe form. Current therapies for MS have limited effect in the progressive stage. Recent studies have confirmed that the primary cause of MS is latent infection with Epstein-Barr virus (EBV). […]
A clinical trial for patients with Myelin oligodendrocyte glycoprotein antibody disorder (MogAD)
This is a Global, Multicentre Phase III, Randomised, Double-Blind Clinical Trial. The study currently includes over 120 adults and is actively recruiting adolescents (12-18 years of age) with MOGAD from around the world. In Australia 3 sites are participating in the study, located in NSW.
Reducing the frequency of Autoimmune adverse events in the treatment of Multiple sclerosis with alemtuzumab using B-celL dEpletion (RAMBLE): a phase II, randomised, placebo-controlled clinical trial
To reduce the occurrence of autoimmune adverse events from the treatment of multiple sclerosis (MS) with alemtuzumab through the subsequent targeted use of rituximab. The hypothesis to be tested is that rituximab therapy following alemtuzumab treatment for MS will reduce the frequency of autoimmune adverse events. If this strategy proves to be safe and is […]
Autologous Haematopoietic Stem Cell Transplantation for highly active treatment resistant multiple sclerosis
We propose to study the benefits and risks of Autologous Haematopoetic Stem Cell Transplant (AHSCT) in people who have an aggressive form of MS not controlled by conventional treatment. Participants will have AHSCT at The Alfred hospital, and they will be closely monitored for 5 years post the transplant to ensure their safety, and also […]